DESCRIPTION
As the pharma industry evolves, it's important to know you are basing your decisions on analysis that reflects the very latest trends and issues. With event-sensitive analysis, you can build your strategy based on analysis and forecasts that are reliable and accurate, to give you the tools to rapidly respond to changes across key diseases areas, companies and drugs.
Evaluate your drug's clinical and commercial potential against related treatments based on emerging clinical trial results and treatment guidelines.
Prioritize market opportunities: Assess revenue potential, competitive threats, market catalysts, and untapped product development opportunities with most up-to-date, comprehensive coverage of drugs, companies, epidemiology, diseases, strategy, and pricing and reimbursement trends.
Identify unmet needs: Gauge the relative strength of upcoming drugs with our drug comparator tool. Identify untapped opportunities.
What's Included
INTRODUCTION
1. Key Findings
2. Market Share of Drug Classes in 2015 and 2025
3. Disease Market SWOT Analysis
ETIOLOGY AND PATHOPHYSIOLOGY
1. Key Findings
2. Expert Insight
3. Disease Overview
4. Disease Pathophysiology
5. Etiology
6. Pathophysiology
KEY PATHWAYS AND DRUG TARGETS
MARKET OUTLOOK
1. Key Findings
2. Expert Insight
3. Market Overview
4. What Factors Are Driving the Market
5. What Factors Are Constraining the Market
Got a question about the product? Email us at support@flevy.com or ask the author directly by using the "Ask the Author a Question" form.
Source: Pharma Disease Insights: Oncology () Document, BigPharma2000
THERE ARE 5 PRODUCTS IN THIS BUNDLE:
|
|
Colorectal cancer therapy market will grow modestly from $8.4 billion in 2015 to $12.5 billion in 2025 in the seven major pharmaceutical markets under study. Growth will be... [read more]
Individual Price: $99.00
|
|
|
In 2015, major-market sales totaled $1.2 billion for gastric and gastroesophageal junction (GEJ) adenocarcinoma. We expect that major-market sales will rapidly increase... [read more]
Individual Price: $99.00
|
|
|
Yielding an mPFS of 6.9 months and MOS of 14.6 months, the Stupp regimen has been the efficacy yardstick and standard treatment protocol followed for newly diagnosed... [read more]
Individual Price: $99.00
|
|
|
The multiple myeloma market will witness an impressive 10% annual growth over 2015-2025, with major-market sales increasing from $8.6 billion in 2015 to $22.3 billion in 2025.... [read more]
Individual Price: $99.00
|
|
|
The breast cancer therapy market was the largest in oncology across the major markets (United States, France, Germany, Italy, Spain, United Kingdom, and Japan) in 2015... [read more]
Individual Price: $99.00
|
